Yulya Timashpolsky, MD
Internal Medicine · Bronx, NYNPI 1114965019
Payments from drug & device makers
Across 31 payments — averaging $25.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$148
- Mayne Pharma Commercial LLC$135
- Millicent US Inc$77
- Gilead$73
- Antares Pharma, Inc.$71
- Evofem Biosciences, Inc.$69
- plus $223 from 6 others
What the payments were for
- Food & beverage$796100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 5 | $148 |
| Mayne Pharma Commercial LLC | 5 | $135 |
| Millicent US Inc | 4 | $77 |
| Gilead | 3 | $73 |
| Antares Pharma, Inc. | 2 | $71 |
| Evofem Biosciences, Inc. | 3 | $69 |
| Johnson & Johnson | 2 | $65 |
| Bayer | 2 | $56 |
| Tolmar, Inc. | 2 | $33 |
| Lilly USA, LLC | 1 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Boston Scientific | 1 | $17 |
How this compares
$796 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril | 46 | $468 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $336 |
| Rosuvastatin Calcium | 60 | $332 |
| Atorvastatin Calcium | 55 | $298 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 19 | $251 |
| Losartan Potassium | 21 | $248 |
| Amlodipine Besylate | 38 | $244 |
| Omeprazole | 33 | $215 |
| Levothyroxine Sodium | 13 | $131 |
| Doxazosin Mesylate | 11 | $110 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 17 | $106 |
| Metformin Hcl | 28 | $78 |
| Lisinopril | 11 | $20 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Bronx
- Benjamin GartrellBronx$6.3M
- David SteinBronx$2.4M
- Haiying ChengBronx$1.7M
- Jason LeiderBronx$1.4M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.